390 related articles for article (PubMed ID: 18562408)
1. Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases.
Akkaya C; Kaya B; Kotan Z; Sarandol A; Ersoy C; Kirli S
J Psychopharmacol; 2009 Aug; 23(6):723-6. PubMed ID: 18562408
[TBL] [Abstract][Full Text] [Related]
2. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
[TBL] [Abstract][Full Text] [Related]
3. Amisulpride-induced hyperprolactinemia is reversible following discontinuation.
Paparrigopoulos T; Liappas J; Tzavellas E; Mourikis I; Soldatos C
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):92-6. PubMed ID: 16938372
[TBL] [Abstract][Full Text] [Related]
4. Hyperprolactinaemia and acute psychosis: prolactinoma or medication-induced phenomenon?
Höfer P; Friedrich F; Vyssoki B; Spindelegger C; Schmook M; Barnas C; Lesch OM; Walter H
World J Biol Psychiatry; 2010 Aug; 11(5):759-61. PubMed ID: 20446883
[No Abstract] [Full Text] [Related]
5. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
Bushe C; Shaw M
J Psychopharmacol; 2007 Sep; 21(7):768-73. PubMed ID: 17606473
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotics and pituitary neoplasms in the WHO database.
Doraiswamy PM; Schott G; Star K; Edwards R; Mueller-Oerlinghausen B
Psychopharmacol Bull; 2007; 40(1):74-6. PubMed ID: 17285098
[TBL] [Abstract][Full Text] [Related]
7. A possible effect of amisulpride on a prolactinoma growth in a woman with borderline personality disorder.
Perroud N; Huguelet P
Pharmacol Res; 2004 Sep; 50(3):377-9. PubMed ID: 15225684
[TBL] [Abstract][Full Text] [Related]
8. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia.
Nakajima M; Terao T; Iwata N; Nakamura J
Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461
[TBL] [Abstract][Full Text] [Related]
9. Cabergoline-induced psychotic exacerbation in schizophrenic patients.
Chang SC; Chen CH; Lu ML
Gen Hosp Psychiatry; 2008; 30(4):378-80. PubMed ID: 18585544
[TBL] [Abstract][Full Text] [Related]
10. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
Zink M; Knopf U; Henn FA; Thome J
Pharmacopsychiatry; 2004 Jan; 37(1):26-31. PubMed ID: 14750045
[TBL] [Abstract][Full Text] [Related]
11. Hyperprolactinemia after low dose of amisulpride.
Kopecek M; Bares M; Svarc J; Dockery C; Horácek J
Neuro Endocrinol Lett; 2004 Dec; 25(6):419-22. PubMed ID: 15665803
[TBL] [Abstract][Full Text] [Related]
12. Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia--a case report with a review of the literature.
Konopelska S; Quinkler M; Strasburger CJ; Ventz M
J Clin Psychopharmacol; 2008 Feb; 28(1):120-2. PubMed ID: 18204364
[No Abstract] [Full Text] [Related]
13. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report.
Bliesener N; Yokusoglu H; Quednow BB; Klingmüller D; Kühn KU
Pharmacopsychiatry; 2004 Jul; 37(4):189-91. PubMed ID: 15467977
[No Abstract] [Full Text] [Related]
14. Normalization of hyperprolactinaemia after withdrawal of a low dose of amisulpride.
Kopecek M; Bares M; Horácek J
Neuro Endocrinol Lett; 2005 Aug; 26(4):320. PubMed ID: 16136015
[No Abstract] [Full Text] [Related]
15. Effect of risperidone on prolactinoma--a case report.
Mendhekar DN; Jiloha RC; Srivastava PK
Pharmacopsychiatry; 2004 Jan; 37(1):41-2. PubMed ID: 14750048
[TBL] [Abstract][Full Text] [Related]
16. Hormonal side effects in women: typical versus atypical antipsychotic treatment.
Dickson RA; Seeman MV; Corenblum B
J Clin Psychiatry; 2000; 61 Suppl 3():10-5. PubMed ID: 10724128
[TBL] [Abstract][Full Text] [Related]
17. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
Lai YC; Chiou CC; Chen CH; Huang MC
J Clin Psychopharmacol; 2007 Oct; 27(5):523-4. PubMed ID: 17873693
[No Abstract] [Full Text] [Related]
18. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
[TBL] [Abstract][Full Text] [Related]
19. Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia.
Poyraz BC; Aksoy C; Balcioğlu I
Eur Neuropsychopharmacol; 2008 Sep; 18(9):667-72. PubMed ID: 18539008
[TBL] [Abstract][Full Text] [Related]
20. Prolactin awareness: an essential consideration for physical health in schizophrenia.
Montejo AL
Eur Neuropsychopharmacol; 2008 May; 18 Suppl 2():S108-14. PubMed ID: 18346598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
